RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 21 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 21

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  3. Study siteCentral Hospital Affiliated to Shandong First Medical University山东第一医科大学附属中心医院(济南市中心医院)JinanHospital page
  4. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  5. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  6. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  7. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  8. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  9. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  10. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  11. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  12. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  13. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  14. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  15. Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
  16. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  17. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  18. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  19. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  20. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  21. Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06966700, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.

    Inclusion criterion 6

    Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory.

    Inclusion criterion 7

  3. cT1c, N1-N2

    Inclusion criterion 2

    cT2, N0-N2

    Inclusion criterion 3

    cT3, N0-N2

    Inclusion criterion 4

    cT4a-d, N0-N2

    Inclusion criterion 5

    Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement

    Exclusion criterion 1

  4. Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment.

    Exclusion criterion 3

    Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1.

    Exclusion criterion 4

    Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).

    Exclusion criterion 5

    Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).

    Exclusion criterion 6

  5. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1).

    Inclusion criterion 8

  6. Known additional malignancy that is progressing or has required active treatment within the past 5 years.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06966700, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment:
  • cT1c, N1-N2
  • cT2, N0-N2
  • cT3, N0-N2
  • cT4a-d, N0-N2
  • The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  • Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory.
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1).
  • Demonstrates adequate organ function.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement
  • Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer
  • Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment.
  • Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1.
  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).
  • Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).
  • Received prior treatment with a topoisomerase I inhibitor-containing ADC.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
  • Known additional malignancy that is progressing or has required active treatment within the past 5 years.
  • Uncontrolled systemic disease.
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening..

Quoted from ClinicalTrials.gov, NCT06966700, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06966700, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06966700